News
Parexel Achieves Top Rankings in Industry Across Multiple Attributes in ISR CRO Phase II-III Benchmarking Report
Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, announced the company has been ranked first among global Clinical Research Organizations (CROs) for Customer Loyalty and in the...
News
MedPharm Expands Its Formulation Development Labs in the UK
MedPharm Ltd, the world leader in formulation and development services for topical and transdermal products, has announced a ยฃ1.5M refurbishment that will increase laboratory space in the UK by 30%.
The renovations will incorporate increased investment in automated technologies to...
Clinical Trials
Bharat Biotechs Covaxin approved for phase 2/3 trials on children
The Drugs Controller General of India (DGCI) has approved Bharat Biotech's COVID-19 vaccine Covaxin for phase II/III clinical trial on those aged between two to 18 years. The trial will take place in 525 subjects at various sites, including...
News
Phesi calls for sponsors to rethink ‘primitive’ clinical trial approaches and adopt modal value guided design
Virtual clinical development specialists, Phesi Inc., are calling for clinical trials to be designed using industry modal values (data values that appear most often in historical trials data) to reduce protocol amendments. Phesi analyzed 330,000 clinical trials from the...
News
Prevention-focused model is important in Indian Healthcare Industry
India has actually always believed in a disease prevention model of healthcare -- the Ayurveda system, which relies heavily on keeping oneโs body and mind in balance and thus, disease-free. In it, disease treatment also focuses on the root...
News
WHO classifies India Covid strain as ‘variant of concern’
The B-1617 variant of coronavirus, first identified in India, has been classified as a โvariant of concernโ at the global level by the World Health Organisation (WHO).
Dr Maria Van Kerkhove, Covid-19 Technical Lead at WHO, on Monday said that...
Clinical Trials
INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine
INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, announced positive safety, tolerability and immunogenicity data from its placebo-controlled and blinded Phase 2...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.















